

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449/P	TO.	•	Complete if Known		
0000111011	5 101 101117 T T T T T T T T T T T T T T T T T T		•	Application Number	09/501,102-Conf. #3404	
INF	ORMATI	ON DI	SCLOSURE	Filing Date	February 9, 2000	
STATEMENT BY APPLICANT				First Named Inventor	Man Sung Co	
J				Art Unit	1644	
	(Use as man)	y sheets as	necessary)	Examiner Name	P. Gambel	
Sheet	1	of	3	Attorney Docket Number	WYS-004.01	

			U.S. PA	TENT DOCUMENTS	
Examiner	63-	Document Number	Publication Date Name of Patentee or		Pages, Columns, Lines, Where
Initials*	Cite No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	opplicant of Cited Document	Relevant Passages or Relevant Figures Appear
	AA*	US-5,397,703	03-14-1995	De Boer et al.	
	AB*	US-5,562,903	10-08-1996	Qo et al.	
	AC*	US-5,622,701	04-22-1997/	Berg	
-	AD*	US-5,869,050	02-09-1999	de Boer et al.	
	AE*	US-5,919,449	07-06 1999	Dinsmore	
	AF*	US-5,977,318	11,02-1999	Linsley et al.	
	AG*	US-6,084,067	97-04-2000	Freeman et al.	
	AH*	US-6,096,537	08-01-2000	Chappel	/
	Al*	US-6,130,316	10-10-2000	Freeman et al.	
	AJ"	US-6,346,248	02-12-2002	De Boer et al.	
	AK*	US-6,608,180	08-19-2003	Sharpe et al.	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	BA /	WO 94/01547	01-20-1994			Г
	BB	WO 95/34320	12/1995			Г
	<b>B</b> C	WO 98/19706	05-14-1998			Г
	BD	WO 00/19706	04-06-2000			Γ

\*EXAN INER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. \*CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filled after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.usoto.gov">www.usoto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*5 or Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sertal number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1		
	CA	Azuma et al., "970 antigen is a second ligand for CTLA-2 and CD28," Nature, 366:76-79 (1993)	
	СВ	Berzofsky et al., "Antigen-Antibody Interaction," in Fundamental Immunology, W.E. Paul eds. (NY: Rayen Press), pp. 595-644 (1984)	
	cc	Bluestone, J.A., "Costimulation and its role in organ transplantation," Clinical Transplantation, 10:194-109 (1996)	
	CD	Chen et al., "Costimulation of Antitumor Immunity by the B7 Counter receptor for the T Lymphocyte Molecules CD28 and CTLA-4," Cell, 71:1093-1102 (1992)	
	CE	Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," The J. of Immunology, 148(4):1149-1154 (1992)	
	CF	Cromwell et al., Abstract The Human PBMC-Reconstituted Nod-Scid Mouse as model of Superantigen-Induced Human T Cell Activation, Experimental Biology 98 Meeting, April 22, 1998	

Examiner	,	Date	
		{Date	
Signature I		Considered	
Signature		Considered	

NOT CONSIDERED

PHUPGANDER 5/3/07

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	stitute for form 1449/P7	· ·		Complete if Known		
"	,			Application Number	09/501,102-Conf. #3404	
11	NFORMATIC	ON DIS	CLOSURE	Filing Date	February 9, 2000	
l s	TATEMENT	BY A	PPLICANT	First Named Inventor	Man Sung Co	
		,		Art Unit	1644	
	(Use as many	sheets as ne	ecessary)	Examiner Name	P. Gambel	
Sheet	2	of	3	Attorney Docket Number	WYS-004.01	

CG Daikh et al., "The CD28-B7 costimulatory pathway and its role in autoimmune disease," J. of Leukooyte Bioli, 62:156-162 (1997)  CH Damico et al., "Pharmacokinetics of IV Administered Murine Anti-Human B7.1 and Murine Anti-Human B7.2 in Cynomolgus Monkeys," Abstract, 17th Annual Scientific Meeting, January 9, 1998  CI Engel et al., "The B7-2 (B70) Costing distory Molecule Expressed by Monocytes and Activated B Lymphocytes is the C086 Differentiation antigen," Blood, 84(5):1402-1407 (1994)  CJ Fleischer et al., "Differential expression and function of CD80 (87-1) and CD86 (87-2) on human peripheral blood prohocytes," Immunology, 89:592-598 (1996)  CK Fujihara et al., "Decryased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B Pradiation: its Involvement in Inactivation of Allogenecity," Blood 87(6):2385-2399 (1998)  CL Glaser et al., "Dissection of the Combining Site in a Humanized Anti-Tac Antibody," The J. of Immunology, 149(8):2607-2614 (1992)  CM Goldberg et al., "Pretreatment of renal transplants with anti-CD45 aptibodies: optimization of perfection technique," Transplant Immunology, 2:27-34 (1994)  I partition and Lane (Eds) Antibodies: A Laboratory Manual, Colespring Harbor Laboratory 1988, pp. 23-35.  CO Hathcock et al., "Identification of an alternative CTLA-4rigand costimulatory for T cell activation," Science 262:905-907 (1993)  CP Jeannin et al., "CD66 (87-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jeffers et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, Eligbardon, Birmingham, pp. 115-128  CR Levint, M., "Molecular Dynamics of Mative Protein," J. Mol. Biol., 168:595-620 (1983)  CS Levin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):121-6 (1997)  CU Morrisons et al., "Complement activation and Fc re			
Anti-Human B7.2 in Cynomolgus Monkeys. Abstract, 17th Annual Scientific Meeting, January 9, 1998  CI Engel et al., "The B7-2 (B70) Costinulatory Molecule Expressed by Monocytes and Activated B Lymphocytes is the CD86 Difforentiation antigen," Blood, 84(5):1402-1407 (1994)  CJ Fleischer et al., "Differential pression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood princytes," Immunology, 89:592-598 (1996)  CK Fujihara et al., "Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B pradiation: its Involvement in Inactivation of Allogenecity," Blood 87(6):2386-2393 (1996)  CL Glaser et al., "Dissection of the Combining Site in a Humanized Anti-Tac Antibody," The J. of immunology, 149(8):2607-2614 (1992)  CM Goldberg et al., "Pretreatment of renal transplants with anti-CD45 antibodies: optimization of perdision technique," Transplant immunology, 2:27-34 (1994)  CN Hafrow and Lane (Eds) Antibodies: A Laboratory Manual, Colespring Harbor Laboratory 1988, pp. 23-35.  CO Hathcock et al., "Identification of an alternative CTLA-Arigand costimulatory for T cell activation," Science 262:905-907 (1993)  CP Jeannin et al., "CD86 (B7-2) on Human B Cells," he J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jeffers et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbaston, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Maive Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," in Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England. Academic Titles), pp. 101-113 (1993)  CV Right et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:80-885 (1996)  CV Right et al., "Differential distribution of B7-1 and B7-2 in hapten-induced contact	CG	Leukocyte Biol., 62:156-162 (1997)	
B Lymphocytes is the CD86 Differination antigen," Blood, 84(5): 1402-1407 (1994)  CJ Fleischer et al., "Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood proncytes," Immunology, 89:592-598 (1996)  CK Fujihara et al., "Decreased Inducible Expression of CD80 and CD86 in Human Monocytes After Ultraviolet-B bradiation: Its Involvement in Inactivation of Allogenecity," Blood 87(6):2386-2393 (1996)  CL Glaser et al., "Dissection of the Combining Site in a Humanized Anti-Tac Antibody," The J. of Immunology, 149(6):2607-2614 (1992)  CM Goldberg et al., "Pretreatment of renal transplants with anti-CD45 antibodies: optimization of perission technique," Transplant Immunology, 2:27-34 (1994)  CN Jafrow and Lane (Eds) Antibodies: A Laboratory Manual, Colespring Harbor Laboratory 1988, pp. 23-35.  CO Hathcock et al., "Identification of an alternative CTLA-Angand costimulatory for T cell activation," Science 262:905-907 (1993)  CP Jannin et al., "CD86 (87-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jefferls et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbarfon, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Maive Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG." In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV Rolls Printouy! Ig gamma-2 chain C region sequence, Accession #P01859, Gi121042 (July 21, 1986)  CW Ohki et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 10:10:104-113 (1997	СН	Anti-Human B7.2 in Cynomolgus Monkeys Abstract, 17th Annual Scientific Meeting, January	
human peripheral blood proncytes," Immunology, 89:592-598 (1996)  CK Fujihara et al., "Decreased Inducible Expression of CB80 and CD86 in Human Mono ytes After Ultraviolet-B Iradiation: Its Involvement in Inactivation of Allogenecity." Blood 87(6):2386-2393/1996)  CL Glaser et al., "Dissection of the Combining Site in a Humanized Anti-Tac Antibody," The J. of Immunology, 149(8):2607-2614 (1992)  CM Goldberg et al., "Pretreatment of renal transplants with anti-CD45 antibodies: optimization of periodion technique," Transplant Immunology, 2:27-34 (1994)  CN Jafrow and Lane (Eds) Antibodies: A Laboratory Manual, Colespring Harbor Laboratory 1988, pp. 23-35.  CO Hathcock et al., "Identification of an alternative CTLA-4 igand costimulatory for T cell activation," Science 262:905-907 (1993)  CP Jeannin et al., "CD86 (B7-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, Epgbarton, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Mative Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Dispase," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Corpetement activation and Fc receptor binding by IgG," in Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printout Ig gamma-2 chain C region sequence, Accession #P01859, Gl121042 (July 21, 1986)  CW NcBI Printout Ig gamma-2 chain C region sequence, Accession #P01859, Gl121042 (July 21, 1986)  CY Rugtveit et al., "Differential distribution of B7-1 and B7-2 in hapten-induced contact sensitivity," Lur. J. Immunol., 26:880-885 (1996)  CX Rugtveit et al., "Diveolopment of Humanized Bispecific Antibodies R	CI	B Lymphocytes is the CD86 Differentiation antigen," Blood, 84(5):1402-1407 (1994)	
After Ultraviolet-B Jradiation: Its Involvement in Inactivation of Allogenecity," Blood 87(6):2386-2393 (1996)  CL Glaser et al., Dissection of the Combining Site in a Humanized Anti-Tac Antibody," The J. of Immunology, 149(8):2607-2614 (1992)  CM Goldberg et al., "Pretreatment of renal transplants with anti-CD45 antibodies: optimization of perfesion technique," Transplant Immunology, 2:27-34 (1994)  CN Parlow and Lane (Eds) Antibodies: A Laboratory Manual, Colespring Harbor Laboratory 1988, pp. 23-35.  CO Hathcock et al., "Identification of an alternative CTLA-4 figand costimulatory for T cell activation," Science 262:905-907 (1993)  CP Jeannin et al., "CD86 (B7-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbardon, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Pative Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Sastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printoux ig gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986)  CW Oki et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Tumop/Rejection After Direct Costimulation of CD8* T Cells	CU	human peripheral blood monocytes," Immunology, 89:592-598 (1996)	
Immunology, 149(8):2607-2614 (1992)  CM Goldbyfg et al., "Pretreatment of renal transplants with anti-CD45 antibodies: optimization of perdsion technique," Transplant Immunology, 2:27-34 (1994)  CN Harlow and Lane (Eds) Antibodies: A Laboratory Manual, Colespring Harbor Laboratory 1988, pp. 23-35.  CO Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-907 (1993)  CP Jeannin et al., "CD86 (B7-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jefferis et al., "Molecular characterization in IgG antibody effector sites," Department of Immunol., The Medical School, EDgbasion, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Jedive Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printoux Ig gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans-cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1998)  CY Rugtveit et al., "Differential distribution of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1998)  CX Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Over	СК	After Ultraviolet-B Irradiation: Its Involvement in Inactivation of Allogenecity," Blood 87(6):2386-2393 (1996)	
perfésion technique," Transplant Immunology, 2:27-34 (1994)  CN barlow and Lane (Eds) Antibodies: A Laboratory Manual, Colespring Harbor Laboratory 1988, pp. 23-35.  CO Hathcock et al., "Identification of an alternative CTLA-digand costimulatory for T cell activation," Science 262:905-907 (1993)  CP Jeannin et al., "CD86 (B7-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbarton, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Mative Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxord University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printout, Ig gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Rofser et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Lur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7-1 (CD80) and B7-2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-2	CL	Immunology, 149(8):2607-2614 (1992)	
pp. 23-35.  CO Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," Science 262:905-907 (1993)  CP Jeannin et al., "CD86 (B7-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbasion, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Mative Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printout Ig gamma-2 chain C region sequence, Accession #P01859, Gl121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B2-2 (CD86) costimulatory molecules on mucosal macrophage subsets in human infarmmatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7-		perfesion technique," Transplant Immunology, 2:27-34 (1994)	
activation," Science 262:905-907 (1993)  CP Jeannin et al., "CD86 (87-2) on Human B Cells," The J. of Biol. Chemistry, 272(25):15613-15619 (1997)  CQ Jefferis et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbaston, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Mative Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Corpolement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printoux Ig gamma-2 chain C region sequence, Accession #P01859, Gl121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 10:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Oxerexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)		pp. 23-35.	
15619 (1997)   Lepteris et al., "Molecular characterization of IgG antibody effector sites," Department of Immunol., The Medical School, EDgbaston, Birmingham, pp. 115-126	СО	activation,* Science 262:905-907 (1993)	
Immunol., The Medical School, EDgbaston, Birmingham, pp. 115-126  CR Levitt, M., "Molecular Dynamics of Mative Protein," J. Mol. Biol., 168:595-620 (1983)  CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printout Ig gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Reser et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B2-2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8" T Cells by B7-		15619 (1997)	
CS Lewin, Benjamin, Genes IV, Oxford University Press, 1990, p. 810  CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Dispase," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printout Ig gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans-cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7-		Immunol., The Medical School, EDgbaston, Birmingham, pp. 115-126	
CT Liu et al., "Increased Expression of Costimulatory Molecules on Peripheral Blood Monocytes in Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printout, Ig gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Reser et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B1/2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8" T Cells by B7-			
Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)  CU Morrisons et al., "Complement activation and Fc receptor binding by IgG," In Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printout, Ig gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B7-2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7-			
Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)  CV NCBI Printout, 1g gamma-2 chain C region sequence, Accession #P01859, GI121042 (July 21, 1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B7-2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8" T Cells by B7-		Patients with Crohn's Disease," Scand. J. Gastroenterol., 32(12):1241-6 (1997)	
1986)  CW Ohki et al., "Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8" T Cells by B7-	CU	Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, M. Clark, eds. (England: Academic Titles), pp. 101-113 (1993)	
atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)  CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity,"  Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD),"  Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8" T Cells by B7-	CV		
CX Refer et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity,"  Eur. J. Immunol., 26:880-885 (1996)  CY Rugtveit et al., "Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD),"  Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8" T Cells by B7-		atopic dermatitis," British J. of Dermatology, 136:838-845 (1997)	
molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)  CZ Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7-	СХ	Reser et al., "Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity," Eur. J. Immunol., 26:880-885 (1996)	
(June 3, 1999)  CA1 Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7-	CY	molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD)," Clin. Exp. Immunol., 110:104-113 (1997)	
Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)  CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7-	CZ	Saltus, Richard, "Drug allows transplants of mismatched bone marrow," The Boston Globe, A1 (June 3, 1999)	
CB1 Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7- Transfected Melanoma Cells," Science, 259:368-369 (1993)	CA1	Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992)	
	CB1	Townsend et al., "Tumor Rejection After Direct Costimulation of CD8* T Cells by B7- Transfected Melanopa Cells," Science, 259:368-369 (1993)	

Examiner		Date	
		Date	
Signature		Considered	
Signature	<u>.</u>	Considered	

NOT CONSIDERED
PHILIPELINGER 5/2/07

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449/P	то		Complete If Known		
0000				Application Number	09/501,102-Conf. #3404	
INF	ORMATI	ON DISC	CLOSURE	Filing Date	February 9, 2000	
STA	TEMEN'	T BY AP	PLICANT	First Named Inventor	Man Sung Co	
		. —		Art Unit	1644	
	(Use as many	y she ets as nec	essary)	Examiner Name	P. Gambel	
Sheet	3	of	3	Attorney Docket Number	WYS-004.01	

ICC4 IVakazaki akal	"Eunetidool CD96 (B7 B70	lan Culturad Humman Langarha	oc Celle " The
i icci itokozekizkal		) on Cultured Human Langerha	IS CEIS. THE
l lo	and the second s	400-447 450 (4000)	
I ISOCIEM/ for Inve	stinative Nermaleimov Inc.	1UD:147-153 (199D)	
	stigative permatelogy, Inc.,	100:11: 100 (1000)	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONSIDERED GAMBEL

PITULIA GAMBEL

J3/07

Examiner Date Considered Signature

Applicant's unique citation designation number (optional). Papplicant is to place a check mark here if English language Translation is attached.